Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 193

1.

Targeting opioid dysregulation in depression for the development of novel therapeutics.

Browne CA, Lucki I.

Pharmacol Ther. 2019 Apr 30. pii: S0163-7258(19)30072-5. doi: 10.1016/j.pharmthera.2019.04.009. [Epub ahead of print]

PMID:
31051197
2.

Deletion of the vesicular monoamine transporter 1 (vmat1/slc18a1) gene affects dopamine signaling.

Lohoff FW, Carr GV, Brookshire B, Ferraro TN, Lucki I.

Brain Res. 2019 Jun 1;1712:151-157. doi: 10.1016/j.brainres.2019.01.029. Epub 2019 Jan 24.

PMID:
30685272
3.

Dysregulation of the Lateral Habenula in Major Depressive Disorder.

Browne CA, Hammack R, Lucki I.

Front Synaptic Neurosci. 2018 Dec 7;10:46. doi: 10.3389/fnsyn.2018.00046. eCollection 2018. Review.

4.

Ketamine Reverses Lateral Habenula Neuronal Dysfunction and Behavioral Immobility in the Forced Swim Test Following Maternal Deprivation in Late Adolescent Rats.

Shepard RD, Langlois LD, Browne CA, Berenji A, Lucki I, Nugent FS.

Front Synaptic Neurosci. 2018 Oct 30;10:39. doi: 10.3389/fnsyn.2018.00039. eCollection 2018.

5.

Opioid modulation of cognitive impairment in depression.

Jacobson ML, Wulf HA, Browne CA, Lucki I.

Prog Brain Res. 2018;239:1-48. doi: 10.1016/bs.pbr.2018.07.007. Epub 2018 Sep 18. Review.

PMID:
30314565
6.

A role for corticotropin-releasing factor signaling in the lateral habenula and its modulation by early-life stress.

Authement ME, Langlois LD, Shepard RD, Browne CA, Lucki I, Kassis H, Nugent FS.

Sci Signal. 2018 Mar 6;11(520). pii: eaan6480. doi: 10.1126/scisignal.aan6480.

7.

Reversal of Stress-Induced Social Interaction Deficits by Buprenorphine.

Browne CA, Falcon E, Robinson SA, Berton O, Lucki I.

Int J Neuropsychopharmacol. 2018 Feb 1;21(2):164-174. doi: 10.1093/ijnp/pyx079.

8.

Genetic variation in the behavioral effects of buprenorphine in female mice derived from a murine model of the OPRM1 A118G polymorphism.

Browne CA, Erickson RL, Blendy JA, Lucki I.

Neuropharmacology. 2017 May 1;117:401-407. doi: 10.1016/j.neuropharm.2017.02.005. Epub 2017 Feb 7.

9.

Hair corticosterone measurement in mouse models of type 1 and type 2 diabetes mellitus.

Erickson RL, Browne CA, Lucki I.

Physiol Behav. 2017 Sep 1;178:166-171. doi: 10.1016/j.physbeh.2017.01.018. Epub 2017 Jan 12.

10.

B. Kenneth Koe.

Lucki I.

Neuropsychopharmacology. 2016 Dec;41(13):3119. doi: 10.1038/npp.2016.152. No abstract available.

11.

A role for the mu opioid receptor in the antidepressant effects of buprenorphine.

Robinson SA, Erickson RL, Browne CA, Lucki I.

Behav Brain Res. 2017 Feb 15;319:96-103. doi: 10.1016/j.bbr.2016.10.050. Epub 2016 Nov 3.

12.

Removal of high-fat diet after chronic exposure drives binge behavior and dopaminergic dysregulation in female mice.

Carlin JL, McKee SE, Hill-Smith T, Grissom NM, George R, Lucki I, Reyes TM.

Neuroscience. 2016 Jun 21;326:170-179. doi: 10.1016/j.neuroscience.2016.04.002. Epub 2016 Apr 8.

PMID:
27063418
13.

Antidepressant-like Effects of Buprenorphine are Mediated by Kappa Opioid Receptors.

Falcon E, Browne CA, Leon RM, Fleites VC, Sweeney R, Kirby LG, Lucki I.

Neuropsychopharmacology. 2016 Aug;41(9):2344-51. doi: 10.1038/npp.2016.38. Epub 2016 Mar 16.

14.

Dexras1 a unique ras-GTPase interacts with NMDA receptor activity and provides a novel dissociation between anxiety, working memory and sensory gating.

Carlson GC, Lin RE, Chen Y, Brookshire BR, White RS, Lucki I, Siegel SJ, Kim SF.

Neuroscience. 2016 May 13;322:408-15. doi: 10.1016/j.neuroscience.2016.02.063. Epub 2016 Mar 3.

PMID:
26946266
15.

Editorial: Reporting guidelines for psychopharmacology.

Steckler T, Curran HV, de Wit H, Howes O, Hoyer D, Lucki I, Miczek KA, Morrow AL, Price LH, Robbins TW.

Psychopharmacology (Berl). 2016 Apr;233(7):1131-4. doi: 10.1007/s00213-016-4252-7. No abstract available.

PMID:
26915651
16.

Corticosterone exposure augments sensitivity to the behavioral and neuroplastic effects of fluoxetine in C57BL/6 mice.

Robinson SA, Brookshire BR, Lucki I.

Neurobiol Stress. 2016 Jan 11;3:34-42. doi: 10.1016/j.ynstr.2015.12.005. eCollection 2016 Jun.

17.

Corticotropin-releasing Factor in the Rat Dorsal Raphe Nucleus Promotes Different Forms of Behavioral Flexibility Depending on Social Stress History.

Snyder KP, Hill-Smith TE, Lucki I, Valentino RJ.

Neuropsychopharmacology. 2015 Oct;40(11):2517-25. doi: 10.1038/npp.2015.98. Epub 2015 Apr 13.

18.

Antidepressant-like effects of buprenorphine in rats are strain dependent.

Browne CA, van Nest DS, Lucki I.

Behav Brain Res. 2015 Feb 1;278:385-92. doi: 10.1016/j.bbr.2014.10.014. Epub 2014 Oct 18.

19.

Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice.

Falcon E, Maier K, Robinson SA, Hill-Smith TE, Lucki I.

Psychopharmacology (Berl). 2015 Mar;232(5):907-15. doi: 10.1007/s00213-014-3723-y. Epub 2014 Sep 3.

20.

Indomethacin reverses decreased hippocampal cell proliferation in streptozotocin-induced diabetic mice.

Ho N, Brookshire BR, Clark JE, Lucki I.

Metab Brain Dis. 2015 Apr;30(2):555-62. doi: 10.1007/s11011-014-9611-7. Epub 2014 Aug 28.

21.

NIDDK international conference report on diabetes and depression: current understanding and future directions.

Holt RI, de Groot M, Lucki I, Hunter CM, Sartorius N, Golden SH.

Diabetes Care. 2014 Aug;37(8):2067-77. doi: 10.2337/dc13-2134.

22.

High fat diet produces brain insulin resistance, synaptodendritic abnormalities and altered behavior in mice.

Arnold SE, Lucki I, Brookshire BR, Carlson GC, Browne CA, Kazi H, Bang S, Choi BR, Chen Y, McMullen MF, Kim SF.

Neurobiol Dis. 2014 Jul;67:79-87. doi: 10.1016/j.nbd.2014.03.011. Epub 2014 Mar 29.

23.

Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants.

Browne CA, Lucki I.

Front Pharmacol. 2013 Dec 27;4:161. doi: 10.3389/fphar.2013.00161. Review.

24.

D-serine deficiency attenuates the behavioral and cellular effects induced by the hallucinogenic 5-HT(2A) receptor agonist DOI.

Santini MA, Balu DT, Puhl MD, Hill-Smith TE, Berg AR, Lucki I, Mikkelsen JD, Coyle JT.

Behav Brain Res. 2014 Feb 1;259:242-6. doi: 10.1016/j.bbr.2013.11.022. Epub 2013 Nov 20.

25.

Effects of diabetes on hippocampal neurogenesis: links to cognition and depression.

Ho N, Sommers MS, Lucki I.

Neurosci Biobehav Rev. 2013 Sep;37(8):1346-62. doi: 10.1016/j.neubiorev.2013.03.010. Epub 2013 May 13. Review.

26.

Reversal of dopamine system dysfunction in response to high-fat diet.

Carlin J, Hill-Smith TE, Lucki I, Reyes TM.

Obesity (Silver Spring). 2013 Dec;21(12):2513-21. doi: 10.1002/oby.20374. Epub 2013 May 29.

27.

Electrophysiological and behavioral responses to ketamine in mice with reduced Akt1 expression.

Featherstone RE, M Tatard-Leitman V, Suh JD, Lin R, Lucki I, Siegel SJ.

Psychopharmacology (Berl). 2013 Jun;227(4):639-49. doi: 10.1007/s00213-013-2997-9. Epub 2013 Feb 8.

28.

Brain monoamines and antidepressant-like responses in MRL/MpJ versus C57BL/6J mice.

Balu DT, Turner JR, Brookshire BR, Hill-Smith TE, Blendy JA, Lucki I.

Neuropharmacology. 2013 Apr;67:503-10. doi: 10.1016/j.neuropharm.2012.11.027. Epub 2012 Dec 6.

29.

VMAT1 deletion causes neuronal loss in the hippocampus and neurocognitive deficits in spatial discrimination.

Multani PK, Hodge R, Estévez MA, Abel T, Kung H, Alter M, Brookshire B, Lucki I, Nall AH, Talbot K, Doyle GA, Lohoff FW.

Neuroscience. 2013 Mar 1;232:32-44. doi: 10.1016/j.neuroscience.2012.11.023. Epub 2012 Nov 29.

30.

Strain differences in the effects of chronic corticosterone exposure in the hippocampus.

Hodes GE, Brookshire BR, Hill-Smith TE, Teegarden SL, Berton O, Lucki I.

Neuroscience. 2012 Oct 11;222:269-80. doi: 10.1016/j.neuroscience.2012.06.017. Epub 2012 Jun 23.

31.

HDAC6 regulates glucocorticoid receptor signaling in serotonin pathways with critical impact on stress resilience.

Espallergues J, Teegarden SL, Veerakumar A, Boulden J, Challis C, Jochems J, Chan M, Petersen T, Deneris E, Matthias P, Hahn CG, Lucki I, Beck SG, Berton O.

J Neurosci. 2012 Mar 28;32(13):4400-16. doi: 10.1523/JNEUROSCI.5634-11.2012.

32.

Depressive phenotypes evoked by experimental diabetes are reversed by insulin.

Ho N, Balu DT, Hilario MR, Blendy JA, Lucki I.

Physiol Behav. 2012 Feb 1;105(3):702-8. doi: 10.1016/j.physbeh.2011.09.003. Epub 2011 Sep 10.

33.

Chronic corticosterone exposure alters postsynaptic protein levels of PSD-95, NR1, and synaptopodin in the mouse brain.

Cohen JW, Louneva N, Han LY, Hodes GE, Wilson RS, Bennett DA, Lucki I, Arnold SE.

Synapse. 2011 Aug;65(8):763-70. doi: 10.1002/syn.20900. Epub 2011 Apr 11.

34.

Serotonin revisited.

Cowen PJ, Lucki I.

Psychopharmacology (Berl). 2011 Feb;213(2-3):167-9. doi: 10.1007/s00213-010-2138-7. Epub 2010 Dec 22. No abstract available.

PMID:
21181118
35.

The role of serotonin receptor subtypes in treating depression: a review of animal studies.

Carr GV, Lucki I.

Psychopharmacology (Berl). 2011 Feb;213(2-3):265-87. doi: 10.1007/s00213-010-2097-z. Epub 2010 Nov 24. Review.

36.

Akt1 deficiency in schizophrenia and impairment of hippocampal plasticity and function.

Balu DT, Carlson GC, Talbot K, Kazi H, Hill-Smith TE, Easton RM, Birnbaum MJ, Lucki I.

Hippocampus. 2012 Feb;22(2):230-40. doi: 10.1002/hipo.20887. Epub 2010 Nov 3.

37.

Fluoxetine treatment induces dose dependent alterations in depression associated behavior and neural plasticity in female mice.

Hodes GE, Hill-Smith TE, Lucki I.

Neurosci Lett. 2010 Oct 22;484(1):12-6. doi: 10.1016/j.neulet.2010.07.084. Epub 2010 Aug 6.

38.

Intracerebral microdialysis during deep brain stimulation surgery.

Kilpatrick M, Church E, Danish S, Stiefel M, Jaggi J, Halpern C, Kerr M, Maloney E, Robinson M, Lucki I, Krizman-Grenda E, Baltuch G.

J Neurosci Methods. 2010 Jun 30;190(1):106-11. doi: 10.1016/j.jneumeth.2010.04.013. Epub 2010 Apr 21.

PMID:
20416339
39.

Early life protein restriction alters dopamine circuitry.

Vucetic Z, Totoki K, Schoch H, Whitaker KW, Hill-Smith T, Lucki I, Reyes TM.

Neuroscience. 2010 Jun 30;168(2):359-70. doi: 10.1016/j.neuroscience.2010.04.010. Epub 2010 Apr 13.

40.

Comparison of the kappa-opioid receptor antagonist DIPPA in tests of anxiety-like behavior between Wistar Kyoto and Sprague Dawley rats.

Carr GV, Lucki I.

Psychopharmacology (Berl). 2010 Jun;210(2):295-302. doi: 10.1007/s00213-010-1832-9. Epub 2010 Apr 6.

41.

Antidepressant and anxiolytic effects of selective 5-HT6 receptor agonists in rats.

Carr GV, Schechter LE, Lucki I.

Psychopharmacology (Berl). 2011 Feb;213(2-3):499-507. doi: 10.1007/s00213-010-1798-7. Epub 2010 Mar 9.

42.

Antidepressant-like effects of kappa-opioid receptor antagonists in Wistar Kyoto rats.

Carr GV, Bangasser DA, Bethea T, Young M, Valentino RJ, Lucki I.

Neuropsychopharmacology. 2010 Feb;35(3):752-63. doi: 10.1038/npp.2009.183. Epub 2009 Nov 18.

43.

Sex-specific effects of chronic fluoxetine treatment on neuroplasticity and pharmacokinetics in mice.

Hodes GE, Hill-Smith TE, Suckow RF, Cooper TB, Lucki I.

J Pharmacol Exp Ther. 2010 Jan;332(1):266-73. doi: 10.1124/jpet.109.158717. Epub 2009 Oct 14.

44.

Corticotropin-releasing factor in the dorsal raphe nucleus: Linking stress coping and addiction.

Valentino RJ, Lucki I, Van Bockstaele E.

Brain Res. 2010 Feb 16;1314:29-37. doi: 10.1016/j.brainres.2009.09.100. Epub 2009 Oct 1. Review.

45.

5-HT(1A) receptor function in major depressive disorder.

Savitz J, Lucki I, Drevets WC.

Prog Neurobiol. 2009 May;88(1):17-31. doi: 10.1016/j.pneurobio.2009.01.009. Epub 2009 Feb 7. Review.

46.

Enhanced sensitivity of the MRL/MpJ mouse to the neuroplastic and behavioral effects of chronic antidepressant treatments.

Balu DT, Hodes GE, Anderson BT, Lucki I.

Neuropsychopharmacology. 2009 Jun;34(7):1764-73. doi: 10.1038/npp.2008.234. Epub 2009 Jan 28.

47.

Flow cytometric analysis of BrdU incorporation as a high-throughput method for measuring adult neurogenesis in the mouse.

Balu DT, Hodes GE, Hill TE, Ho N, Rahman Z, Bender CN, Ring RH, Dwyer JM, Rosenzweig-Lipson S, Hughes ZA, Schechter LE, Lucki I.

J Pharmacol Toxicol Methods. 2009 Mar-Apr;59(2):100-7. doi: 10.1016/j.vascn.2008.12.002. Epub 2008 Dec 14.

48.

Variation in the genes encoding vesicular monoamine transporter 2 and beta-1 adrenergic receptor and antidepressant treatment outcome.

Crowley JJ, Lipsky RH, Lucki I, Berrettini WH.

Psychiatr Genet. 2008 Oct;18(5):248-51. doi: 10.1097/YPG.0b013e3283052ff7.

PMID:
18797399
49.

Adult hippocampal neurogenesis: regulation, functional implications, and contribution to disease pathology.

Balu DT, Lucki I.

Neurosci Biobehav Rev. 2009 Mar;33(3):232-52. doi: 10.1016/j.neubiorev.2008.08.007. Epub 2008 Aug 19. Review.

50.

Antidepressant-like behavioral effects of IGF-I produced by enhanced serotonin transmission.

Hoshaw BA, Hill TI, Crowley JJ, Malberg JE, Khawaja X, Rosenzweig-Lipson S, Schechter LE, Lucki I.

Eur J Pharmacol. 2008 Oct 10;594(1-3):109-16. doi: 10.1016/j.ejphar.2008.07.023. Epub 2008 Jul 17.

Supplemental Content

Support Center